Nektar receives Nasdaq delisting notice for bid price below $1.00

NEKTAR THERAPEUTICS

Received Nasdaq notice on April 3, 2025 for non-compliance with minimum bid price rule.
Must regain compliance by September 30, 2025; closing bid price must be at least $1.00 for 10 consecutive days.
If not compliant by deadline, Nasdaq may grant second 180-day grace period subject to conditions.
Company intends to monitor bid price and consider options to regain compliance; no guarantee of success.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.